Lantern Pharma charts course for IPO with AI platform that shines light on failed cancer drugs
Artificial intelligence — the cure-all for the pesky process of making a therapeutic, including data mining, drug discovery, optimal drug delivery and addressable patient population — is being employed by yet another biotech: Lantern Pharma.
The company, which uses its AI platform to identify patients that could benefit from its targeted oncology therapies, on Thursday unveiled plans to make its public debut in an up to $29 million IPO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.